Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Edwards PASCAL Precision Wins FDA Approval as the Second Catheter Repair Option for ...

24 October 2026 · By · Wire by Fusion42

Published

24 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 25 October 2026 · Fusion42 review

The FDA has approved Edwards' PASCAL Precision system as a second option for catheter-based repair of severely leaking tricuspid valves, expanding minimally invasive treatment choices for this heart condition.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 21 Oct 2026 and 24 Oct 2026.

◆ ◆ The Wire takeaway

You face growing competition in tricuspid valve repair as Edwards now has an FDA-approved alternative device. Move to evaluate how PASCAL Precision affects your market positioning or consider partnerships before it undercuts your share.

◆ Coverage

4 sources · first reported 21 Oct 2026 · latest 24 Oct 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalcatheter-repairtricuspid-valvemedical-devicecardiology